Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review
Authors' conclusion
Neoadjuvant MKIs in locally advanced DTC may improve resection rates.
Study context
- Population
- Patients with locally advanced differentiated thyroid cancer (DTC) receiving neoadjuvant MKI before surgery
- Participants
- 119 patients23 observational studies
- Outcome
- Surgical and oncological outcomes
Methodological detailsLenvatinib most frequently used MKI, followed by sorafenib, Search of PubMed, Cochrane Library, Scopus and EMBASE, no time restrictions, 12 case reports, 9 case series, 2 prospective phase II studies
- Lenvatinib most frequently used MKI, followed by sorafenib
- Search of PubMed, Cochrane Library, Scopus and EMBASE, no time restrictions
- 12 case reports, 9 case series, 2 prospective phase II studies
Pooled result
As reported in the abstract
Tumor volume reduction range
25% to 87%
Partial response rate range
33.3% to 76.9%
Progressive disease
7 cases
Underwent surgery, of 114 with inoperable or potentially resectable tumors with high perioperative morbidity
95
83.3%
Original publication
Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review. Thyroid. Published 13 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →